deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03102606

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (Protective-1)

A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)

Sponsor: BeyondSpring Pharmaceuticals Inc.

Conditions Chemotherapy-induced Neutropenia
Interventions D5W Placebo Pegfilgrastim Plinabulin Saline Placebo
Updated 16 times since 2017 Last updated: Aug 24, 2024 Started: May 29, 2018 Primary completion: Dec 12, 2018 Completion: Feb 8, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chemotherapy-induced Neutropenia and is currently completed. BeyondSpring Pharmaceuticals Inc. leads this study, which shows 16 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Jan 2019 · 5 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Jan 2020 · 9 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Dec 2020 · 4 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jul 2024 · 40 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Mar 2021 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

▶ Show 11 earlier versions

  1. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Aug 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Apr 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

    Status: Active Not Recruiting → Recruiting · Phase: PHASE2_PHASE3 → PHASE3

  4. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  5. Jan 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  6. Apr 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE2_PHASE3

  8. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE2_PHASE3

  9. Aug 2018 — Jan 2019 [monthly]

    Recruiting PHASE2_PHASE3

  10. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2_PHASE3

  11. May 2017 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeyondSpring Pharmaceuticals Inc.
  • Covance
  • ICON plc
Data source: BeyondSpring Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Dnipro, Ukraine , Harbin, China , Ivano-Frankivsk, Ukraine , Kherson, Ukraine , Kryvyi Rih, Ukraine , Linyi, China , Louisville, United States , Lviv, Ukraine , Nanjing, China and 8 more locations